Sign In
Buy NYXH
$2.87
-0.100 (-3.37%)
At Close: Jun 03, 2026
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
04:05pm, Friday, 19'th Dec 2025
Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah”
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
01:05am, Wednesday, 17'th Dec 2025
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals
Publication relating to transparency notifications
04:30pm, Tuesday, 02'nd Dec 2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 M
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System
10:16am, Monday, 01'st Dec 2025
Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
04:05pm, Thursday, 27'th Nov 2025
Nyxoah to Participate in the Piper Sandler 37 th Annual Healthcare Conference
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
01:45am, Wednesday, 26'th Nov 2025
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by
Information on the total number of voting rights and shares
04:30pm, Thursday, 20'th Nov 2025
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of
Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript
09:01pm, Thursday, 13'th Nov 2025
Nyxoah SA ( NYXH ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Pearson Dennis Olivier Taelman - CEO & Executive Director John Landry - Chief Financial Officer Conference C
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
07:30pm, Thursday, 13'th Nov 2025
INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U. S. $77 Million to Drive U. S. Commercialization of Genio Financings are comprised of
Nyxoah SA (NYXH) Reports Q3 Loss, Beats Revenue Estimates
06:55pm, Thursday, 13'th Nov 2025
Nyxoah SA (NYXH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to a loss of $0.55 per share a year ago.
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
04:36pm, Thursday, 13'th Nov 2025
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, includi
Nyxoah Reports Third Quarter 2025 Financial and Operating Results
04:12pm, Thursday, 13'th Nov 2025
REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives
Nyxoah to Participate in the Stifel 2025 Healthcare Conference
04:05pm, Monday, 03'rd Nov 2025
Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
05:10pm, Thursday, 30'th Oct 2025
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for
11:10am, Wednesday, 29'th Oct 2025
Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
